Endocannabinoid System Components as Potential Biomarkers in Psychiatry

Area of Science:

• Neuroscience
• Psychiatry
• Biomarker Discovery

Background:

• Psychiatric disorders exhibit high heterogeneity, hindering diagnostic precision.
• Personalized medicine in psychiatry necessitates the identification of reliable biomarkers.
• The endocannabinoid system (ECS) is increasingly recognized for its role in brain functions like emotion, motivation, and cognition.

Purpose of the Study:

• To review the role of ECS components as potential biomarkers in psychiatric disorders.
• To analyze evidence from preclinical and clinical studies on ECS alterations in mental health conditions.
• To explore the therapeutic potential of modulating the ECS.

Main Methods:

• Review of rodent studies on cannabinoid receptor and endocannabinoid (eCB) manipulation.
• Analysis of molecular alterations in animal models of psychiatric disorders.
• Examination of clinical studies on genetic and protein alterations in post-mortem tissues and biofluids (blood, plasma, CSF).
• Inclusion of neuroimaging data (PET, fMRI).

Main Results:

• Cannabinoid receptor 1 (CB1r) is closely linked to stress regulation and mood disorders (anxiety, depression, bipolar disorder).
• CB1r involvement is noted in post-traumatic stress disorder (PTSD), schizophrenia, ADHD, and eating disorders.
• Modulating the ECS, via inhibiting eCB degrading enzymes or targeting CB2r, shows potential therapeutic effects (anxiolytic, antidepressive, antipsychotic).

Conclusions:

• Components of the ECS are promising biomarkers for improving psychiatric diagnosis.
• ECS modulation offers potential therapeutic strategies for psychiatric disorders.
• Further clinical research is required to validate these findings and advance personalized psychiatric treatment.